NuVasive, Inc.  

(Public, NASDAQ:NUVA)   Watch this stock  
Find more results for nuvasive
44.38
+1.02 (2.35%)
Real-time:   12:31PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 42.99 - 44.40
52 week 31.35 - 51.23
Open 43.38
Vol / Avg. 293,747.00/760,967.00
Mkt cap 2.14B
P/E     -
Div/yield     -
EPS -0.37
Shares 48.15M
Beta 0.95
Inst. own 101%
May 11, 2015
NuVasive�, Inc. Annual Shareholder Meeting (Estimated) Add to calendar
May 4, 2015
Q1 2015 NuVasive Inc Earnings Call - 4:30PM EDT - Add to calendar
May 4, 2015
Q1 2015 NuVasive Inc Earnings Release - 4:00PM EDT - Add to calendar
Mar 12, 2015
NuVasive Inc at Barclays Healthcare Conference - Webcast
Mar 2, 2015
NuVasive Inc at Cowen Health Care Conference - Webcast
Feb 24, 2015
Q4 2014 NuVasive Inc Earnings Call - Webcast
Feb 24, 2015
Q4 2014 NuVasive Inc Earnings Release
Feb 11, 2015
NuVasive�, Inc. at the Leerink Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 3.57% -2.29%
Operating margin 12.02% 2.38%
EBITD margin - 16.36%
Return on average assets 2.24% -1.39%
Return on average equity 4.74% -2.71%
Employees 1,500 -
CDP Score - -

Address

7475 Lusk Blvd
SAN DIEGO, CA 92121-5707
United States - Map
+1-858-9091800 (Phone)
+1-800-4759134 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NuVasive, Inc. is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is product portfolio is focused on applications for spine fusion surgery, including biologics. Its principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery (MAS). The product platform includes its software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and Intra-Operative Monitoring (IOM) support; MaXcess, an integrated split-blade retractor system, and a variety of specialized implants. Its biologic product line offerings used to aid the spinal fusion process or bone healing include allograft (donated human tissue), Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells, or MSCs, FormaGraft, a collagen synthetic product, and AttraX, a synthetic bone graft material.

Officers and directors

Gregory T. Lucier Interim Chief Executive Officer, Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Patrick W. G. Miles President, Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Quentin S Blackford Chief Financial Officer, Chief Accounting Officer
Age: 35
Bio & Compensation  - Reuters
Jason M. Hannon Executive Vice President - Corporate Development, General Counsel, Secretary
Age: 42
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew W. Link Executive Vice President - U.S. Sales
Age: 39
Bio & Compensation  - Reuters
Mike Paolucci Executive Vice President - Global Human Resources
Age: 54
Bio & Compensation  - Reuters
Carol Cox Executive Vice President - Strategy and Corporate Communications
Bio & Compensation  - Reuters
Russell A. Powers Executive Vice President - International
Age: 44
Bio & Compensation  - Reuters
Jack R. Blair Independent Director
Age: 71
Bio & Compensation  - Reuters
Peter C. Farrell Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters